The plasma pharmacokinetics and cerebrospinal fluid penetration of the thymidylate synthase inhibitor raltitrexed (TomudexTM) in a nonhuman primate model Brigitte C. WidemannFrank M. BalisPeter C. Adamson ORIGINAL ARTICLE Pages: 439 - 443
Apoptotic cell death induced by baccatin III, a precursor of paclitaxel, may occur without G2/M arrest Merrill C. Miller IIIKorey R. JohnsonWeimin Fan ORIGINAL ARTICLE Pages: 444 - 452
Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients Jim CassidyChris TwelvesBruno Reigner ORIGINAL ARTICLE Pages: 453 - 460
Treatment of poor-prognosis extensive disease small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide – a Southwest Oncology Group clinical and pharmacokinetic study Steven M. GrunbergJohn CrowleyDavid R. Gandara ORIGINAL ARTICLE Pages: 461 - 468
The pharmacokinetics of epirubicin and docetaxel in combination in rats Marie SandströmLena E. SimonsenMats O. Karlsson ORIGINAL ARTICLE Pages: 469 - 474
Difluoromethylornithine in combination with tamoxifen in female rats: 13-week oral toxicity study Alan P. BrownRobert L. MorrisseyBarry S. Levine ORIGINAL ARTICLE Pages: 475 - 483
Erucylphosphocholine: pharmacokinetics, biodistribution and CNS-accumulation in the rat after intravenous administration Bernhard ErdlenbruchVerena JendrossekMax Lakomek ORIGINAL ARTICLE Pages: 484 - 490
Wortmannin inhibits the growth of mammary tumors despite the existence of a novel wortmannin-insensitive phosphatidylinositol-3-kinase Leslie E. LemkeGillian D. Paine-MurrietaGarth Powis ORIGINAL ARTICLE Pages: 491 - 497
WR-2721 (amifostine) infusion in patients with Ewing's sarcoma receiving ifosfamide and cyclophosphamide with mesna: drug and thiol levels in plasma and blood cells, a Pediatric Oncology Group study Abdul-Kader SouidRobert C. FaheyMark L. Bernstein ORIGINAL ARTICLE Pages: 498 - 504
Hepatic arterial infusion chemotherapy for unresectable confined liver metastases: prediction of systemic toxicity with the application of a scintigraphic and pharmacokinetic approach Ettore PelosiFabrizio BarGianni Bisi ORIGINAL ARTICLE Pages: 505 - 510
A phase II trial of CI-958 in patients with hormone-refractory prostate cancer Paul V. WoolleyFuad S. FreihaDonald L. Trump CLINICAL TRIAL REPORT Pages: 511 - 517
A phase II trial of DA-125, a novel anthracycline, in advanced non-small-cell lung cancer Y.-K. KangB.-Y. RyooC.-T. Lee CLINICAL TRIAL REPORT Pages: 518 - 521
